{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:29:32Z","timestamp":1786116572343,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.eururo.2026.03.002","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:34:33Z","timestamp":1776288873000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Considerations for Earlier Use of Radiopharmaceutical Therapy in Prostate Cancer"],"prefix":"10.1016","volume":"90","author":[{"given":"Marc B.","family":"Garnick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Nordquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaemus","family":"Gleason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Estafanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur J.A.T.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.03.002_b0005","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2967\/jnumed.125.270704","article-title":"First-line [177Lu]Lu-PSMA-617 therapy without ADT, chemotherapy, or local therapy for metastatic hormone-sensitive prostate cancer","volume":"66","author":"Giri","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.03.002_b0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: Screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.03.002_b0015","doi-asserted-by":"crossref","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate cancer, version 3.2026, NCCN clinical practice guidelines in oncology","volume":"23","author":"Spratt","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2026.03.002_b0020","first-page":"2311","article-title":"Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline clinical insights","volume":"43","author":"Garje","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.eururo.2026.03.002_b0025","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Electronic address: clinicalguidelines@esmo.org. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.03.002_b0030","unstructured":"EAU guidelines. Edn. presented at the EAU Annual Congress. Madrid, Spain.; 2025. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Urological-infections-2025_2025-05-24-110339_pxmf.pdf."},{"key":"10.1016\/j.eururo.2026.03.002_b0035","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.03.002_b0040","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.03.002_b0045","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.03.002_b0050","doi-asserted-by":"crossref","unstructured":"Raab G, Okobi T.J, Holmes A.N, et al. Mature phase 1 follow-up of alpha emitter 225Ac-J591 with 177Lu-PSMA-I&T in advanced prostate cancer. J Clin Oncol 2025;43(5_suppl):185.","DOI":"10.1200\/JCO.2025.43.5_suppl.185"},{"key":"10.1016\/j.eururo.2026.03.002_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1483953","article-title":"Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial","volume":"14","author":"Hansen","year":"2025","journal-title":"Front Oncol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2026.03.002_b0060","first-page":"LBA65","article-title":"Efficacy of 177Lu-PNT2002 in PSMA-positive metastatic castration-resistant prostate cancer following progression on an androgen receptor pathway inhibitor (SPLASH)","volume":"35","author":"Sartor","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.03.002_b0065","unstructured":"ClinicalTrials.gov. 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer. https:\/\/clinicaltrials.gov\/study\/NCT05204927."},{"key":"10.1016\/j.eururo.2026.03.002_b0070","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.annonc.2025.07.003","article-title":"Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Fizazi","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.03.002_b0075","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","article-title":"Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.03.002_b0080","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.03.002_b0085","doi-asserted-by":"crossref","unstructured":"Tagawa ST, Sartor O, Piulats JM, et al. Phase 3 trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). LBA6, ESMO Congress 2025. https:\/\/www.medicalcongresspresentations.com\/ESMO25\/PC\/pdf\/Tagawa_Oral_LBA6.pdf.","DOI":"10.1016\/j.annonc.2025.09.101"},{"key":"10.1016\/j.eururo.2026.03.002_b0090","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.ijrobp.2025.06.1008","article-title":"177Lu-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer: primary endpoint analysis of the phase II LUNAR randomized trial","volume":"123","author":"Kishan","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2026.03.002_b0095","unstructured":"Sayyid RK. ASCO 2025: BULLSEYE trial; UroToday. https:\/\/www.urotoday.com\/conference-highlights\/asco-2025\/asco-2025-prostate-cancer\/161025-asco-2025-lutetium-177-psma-617-in-oligo-metastatic-hormone-sensitive-prostate-cancer-bullseye-trial.html."},{"issue":"16_suppl","key":"10.1016\/j.eururo.2026.03.002_b0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5127","article-title":"PSMA-delay castration (DC): an open-label, multicentre, randomized phase 3 study of [177Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate cancer","volume":"43","author":"Sartor","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.002_b0105","doi-asserted-by":"crossref","unstructured":"van der Sar E.C.A, Braat A.J.A.T, van der Voort-van Zyp J.R.N, et al. Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment na\u00efve patients, phase I study (PROQURE-I trial). BMC Cancer 2023;23:268. https:\/\/doi.org\/10.1186\/s12885-023-10725-5.","DOI":"10.1186\/s12885-023-10725-5"},{"key":"10.1016\/j.eururo.2026.03.002_b0110","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","article-title":"Administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1\/2 study","volume":"85","author":"Eapen","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.03.002_b0115","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.euo.2022.09.002","article-title":"Neoadjuvant 177Lu-PSMA-I&T radionuclide treatment in patients with high-risk prostate cancer before radical prostatectomy: a single-arm phase 1 trial","volume":"6","author":"Golan","year":"2023","journal-title":"Eur Urol Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826020361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826020361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:31:52Z","timestamp":1786015912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826020361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0302283826020361"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.03.002","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considerations for Earlier Use of Radiopharmaceutical Therapy in Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}